{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T20:01:16Z","timestamp":1784404876270,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104732","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T22:54:14Z","timestamp":1770591254000},"page":"104732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world treatment patterns and sequencing in patients with advanced \/ metastatic HR+\/HER2- breast cancer in Europe and the United States"],"prefix":"10.1016","volume":"86","author":[{"given":"Reshma","family":"Mahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Korytowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe Grace","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-1503","authenticated-orcid":false,"given":"Annabel","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2026.104732_bib2","year":"2023","journal-title":"Breast Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104732_bib3","first-page":"480","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.breast.2026.104732_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","article-title":"Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome","volume":"141","author":"Lobbezoo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"10.1016\/j.breast.2026.104732_bib5","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with Estrogen receptor-positive, HER2-Negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104732_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-024-07469-6","article-title":"Trends in HR+ metastatic breast cancer survival before and after CDK4\/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer","volume":"208","author":"Brufsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2026.104732_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/NCC.0000000000000623","article-title":"Impact of comorbidity on symptoms and quality of life among patients being treated for breast cancer","volume":"42","author":"Wu","year":"2019","journal-title":"Cancer Nurs"},{"issue":"3","key":"10.1016\/j.breast.2026.104732_bib8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10549-011-1819-1","article-title":"Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008","volume":"131","author":"Land","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2026.104732_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.11673","article-title":"Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer","volume":"6","author":"Cannioto","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1158\/1055-9965.EPI-18-0674","article-title":"Adult physical activity and breast cancer risk in women with a family history of breast cancer","volume":"28","author":"Niehoff","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"35","key":"10.1016\/j.breast.2026.104732_bib11","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-Negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104732_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104732_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.breast.2026.104732_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care"},{"issue":"28","key":"10.1016\/j.breast.2026.104732_bib15","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104732_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092161","article-title":"PI3K inhibitors in advanced breast cancer: the past, the present, new challenges and future perspectives","volume":"14","author":"Fuso","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-022-00411-3","article-title":"PARP inhibition in breast cancer: progress made and future hopes","volume":"8","author":"Tung","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/medicina60010168","article-title":"Exploring biomarkers in breast cancer: Hallmarks of diagnosis, treatment, and Follow-Up in clinical practice","volume":"60","author":"Lopez-Gonzalez","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.breast.2026.104732_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/s12885-024-12269-8","article-title":"Systematic literature review of real-world evidence for treatments in HR+\/HER2- second-line LABC\/mBC after first-line treatment with CDK4\/6i","volume":"24","author":"Lambert","year":"2024","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.breast.2026.104732_bib21","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.breast.2026.104732_bib22","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.breast.2026.104732_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2026.104732_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"10.1016\/j.breast.2026.104732_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.breast.2026.104732_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jgo.2021.12.017","article-title":"Overview of Sankey flow diagrams: focusing on symptom trajectories in older adults with advanced cancer","volume":"13","author":"Otto","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.breast.2026.104732_bib28","series-title":"Intellegence reporter version 7.5. mission hills, CA","year":"2021"},{"issue":"12","key":"10.1016\/j.breast.2026.104732_bib29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"20","key":"10.1016\/j.breast.2026.104732_bib31","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104732_bib32","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","article-title":"Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results","volume":"22","author":"Loibl","year":"2017","journal-title":"Oncologist"},{"issue":"32","key":"10.1016\/j.breast.2026.104732_bib33","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Cancer"},{"issue":"25","key":"10.1016\/j.breast.2026.104732_bib35","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104732_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","article-title":"CDK4\/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, ribociclib and abemaciclib","volume":"33","author":"Eggersmann","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.breast.2026.104732_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.breast.2020.09.008","article-title":"Ribociclib plus fulvestrant for advanced breast cancer: health-related quality-of-life analyses from the MONALEESA-3 study","volume":"54","author":"Fasching","year":"2020","journal-title":"Breast"},{"issue":"9","key":"10.1016\/j.breast.2026.104732_bib38","first-page":"e1346","article-title":"Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2- advanced","volume":"25","author":"Goetz","year":"2020","journal-title":"Breast Cancer Oncologist"},{"key":"10.1016\/j.breast.2026.104732_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920943065","article-title":"Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)","volume":"12","author":"Harbeck","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104732_bib40","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0111","article-title":"A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib","volume":"13","author":"Samjoo","year":"2024","journal-title":"J Comp Eff Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104732_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/fon-2018-0531","article-title":"Treatment satisfaction in women receiving palbociclib combination therapies for advanced\/metastatic breast cancer","volume":"15","author":"Darden","year":"2019","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104732_bib42","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-Negative metastatic breast cancer-capivasertib-fulvestrant: ASCO rapid recommendation update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104732_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104732_bib44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000511209","article-title":"Bringing greater accuracy to Europe's healthcare systems: the unexploited potential of biomarker testing in oncology","volume":"5","author":"Horgan","year":"2020","journal-title":"Biomed Hub"},{"issue":"13","key":"10.1016\/j.breast.2026.104732_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133431","article-title":"Real world experience of second-line treatment strategies after palbociclib and letrozole: overall survival in metastatic hormone receptor-positive human epidermal growth factor receptor 2-Negative breast cancer","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104732_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104535","article-title":"A therapeutic algorithm guiding subsequent therapy selection after CDK4\/6 inhibitors' failure: a review of current and investigational treatment for HR+\/Her2- breast cancer","volume":"204","author":"Astore","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"10.1016\/j.breast.2026.104732_bib47","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.breast.2026.104732_bib50","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104732_bib53","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104732_bib56","doi-asserted-by":"crossref","first-page":"TPS1118","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1118","article-title":"A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+\/HER2- advanced breast cancer previously treated with a CDK4\/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1)","volume":"41","author":"Hurvitz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104732_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.027","article-title":"LBA17 gedatolisib (geda) + fulvestrant \u00b1 palbociclib (palbo) vs fulvestrant in patients (pts) with HR+\/HER2-\/PIK3CA wild-type (WT) advanced breast cancer (ABC): first results from VIKTORIA-1","volume":"36","author":"Hurvitz","year":"2025","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104732_bib58","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-Mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104732_bib60","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104732_bib61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104732_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.11.018","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase 3 EMBER-3 trial","author":"Jhaveri","year":"2026","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104732_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1135","article-title":"OPERA-01: a randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4\/6 inhibitors","volume":"42","author":"Pistilli","year":"2024","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.breast.2026.104732_bib66","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104732_bib67","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104732_bib68","series-title":"San antonio breast cancer symposium (SABCS)","article-title":"PD10-03 subgroup analyses of VERITAC-2: a phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive\/human epidermal growth factor receptor 2 (HER2)-Negative advanced breast cancer (aBC)","author":"Hamilton ea","year":"2026"},{"issue":"29","key":"10.1016\/j.breast.2026.104732_bib69","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-Positive\/Human epidermal growth factor receptor 2-Negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10411","key":"10.1016\/j.breast.2026.104732_bib70","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104732_bib74","article-title":"GS1-09 sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+\/HER2\u2212 (IHC 0, 1+, 2+\/ISH\u2212) metastatic breast cancer: primary results from ASCENT-07","author":"Jhaveri ea","year":"2026","journal-title":"San Antonio Breast Cancer Symposium (SABCS)"},{"issue":"1","key":"10.1016\/j.breast.2026.104732_bib75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2026.104732_bib76","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2026.104732_bib77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-Negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:29:17Z","timestamp":1775683757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":64,"alternative-id":["S0960977626000421"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104732","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and sequencing in patients with advanced \/ metastatic HR+\/HER2- breast cancer in Europe and the United States","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104732"}}